-
Developing a Blocker of Alpha-synuclein production – Research
Can anyone please provide information regarding the Syn-516 study? I believe it was being carried out by Jack Timothy Rogers, PhD. and the principle investigator is Dr. Catherine Cahill. connects.catalyst.harvard.edu states that it is suppose to commence on Jan. 31, 2021. Quote, “Our most promising therapeutic compound, Syn-516…”
Sorry, there were no replies found.
Log in to reply.